194 related articles for article (PubMed ID: 22990745)
1. UBE4B levels are correlated with clinical outcomes in neuroblastoma patients and with altered neuroblastoma cell proliferation and sensitivity to epidermal growth factor receptor inhibitors.
Zage PE; Sirisaengtaksin N; Liu Y; Gireud M; Brown BS; Palla S; Richards KN; Hughes DP; Bean AJ
Cancer; 2013 Feb; 119(4):915-23. PubMed ID: 22990745
[TBL] [Abstract][Full Text] [Related]
2. Low UBE4B expression increases sensitivity of chemoresistant neuroblastoma cells to EGFR and STAT5 inhibition.
Memarzadeh K; Savage DJ; Bean AJ
Cancer Biol Ther; 2019; 20(12):1416-1429. PubMed ID: 31475882
[TBL] [Abstract][Full Text] [Related]
3. UBE4B protein couples ubiquitination and sorting machineries to enable epidermal growth factor receptor (EGFR) degradation.
Sirisaengtaksin N; Gireud M; Yan Q; Kubota Y; Meza D; Waymire JC; Zage PE; Bean AJ
J Biol Chem; 2014 Jan; 289(5):3026-39. PubMed ID: 24344129
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin-resistant neuroblastoma cells express enhanced levels of epidermal growth factor receptor (EGFR) and are sensitive to treatment with EGFR-specific toxins.
Michaelis M; Bliss J; Arnold SC; Hinsch N; Rothweiler F; Deubzer HE; Witt O; Langer K; Doerr HW; Wels WS; Cinatl J
Clin Cancer Res; 2008 Oct; 14(20):6531-7. PubMed ID: 18927293
[TBL] [Abstract][Full Text] [Related]
5. Neuroblastoma patient outcomes, tumor differentiation, and ERK activation are correlated with expression levels of the ubiquitin ligase UBE4B.
Woodfield SE; Guo RJ; Liu Y; Major AM; Hollingsworth EF; Indiviglio S; Whittle SB; Mo Q; Bean AJ; Ittmann M; Lopez-Terrada D; Zage PE
Genes Cancer; 2016 Jan; 7(1-2):13-26. PubMed ID: 27014418
[TBL] [Abstract][Full Text] [Related]
6. Screening for gene mutations in a 500 kb neuroblastoma tumor suppressor candidate region in chromosome 1p; mutation and stage-specific expression in UBE4B/UFD2.
Krona C; Ejeskär K; Abel F; Kogner P; Bjelke J; Björk E; Sjöberg RM; Martinsson T
Oncogene; 2003 Apr; 22(15):2343-51. PubMed ID: 12700669
[TBL] [Abstract][Full Text] [Related]
7. Expression and prognostic role of ubiquitination factor E4B in primary hepatocellular carcinoma.
Zhang XF; Pan QZ; Pan K; Weng DS; Wang QJ; Zhao JJ; He J; Liu Q; Wang DD; Jiang SS; Zheng HX; Lv L; Chen CL; Zhang HX; Xia JC
Mol Carcinog; 2016 Jan; 55(1):64-76. PubMed ID: 25557723
[TBL] [Abstract][Full Text] [Related]
8. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
[TBL] [Abstract][Full Text] [Related]
9. The two human homologues of yeast UFD2 ubiquitination factor, UBE4A and UBE4B, are located in common neuroblastoma deletion regions and are subject to mutations in tumours.
Carén H; Holmstrand A; Sjöberg RM; Martinsson T
Eur J Cancer; 2006 Feb; 42(3):381-7. PubMed ID: 16386891
[TBL] [Abstract][Full Text] [Related]
10. UBE4B interacts with the ITCH E3 ubiquitin ligase to induce Ku70 and c-FLIPL polyubiquitination and enhanced neuroblastoma apoptosis.
Le Clorennec C; Subramonian D; Huo Y; Zage PE
Cell Death Dis; 2023 Nov; 14(11):739. PubMed ID: 37957138
[TBL] [Abstract][Full Text] [Related]
11. Signaling of ERBB receptor tyrosine kinases promotes neuroblastoma growth in vitro and in vivo.
Richards KN; Zweidler-McKay PA; Van Roy N; Speleman F; Trevino J; Zage PE; Hughes DP
Cancer; 2010 Jul; 116(13):3233-43. PubMed ID: 20564646
[TBL] [Abstract][Full Text] [Related]
12. UBE4B promotes Hdm2-mediated degradation of the tumor suppressor p53.
Wu H; Pomeroy SL; Ferreira M; Teider N; Mariani J; Nakayama KI; Hatakeyama S; Tron VA; Saltibus LF; Spyracopoulos L; Leng RP
Nat Med; 2011 Mar; 17(3):347-55. PubMed ID: 21317885
[TBL] [Abstract][Full Text] [Related]
13. A novel therapeutic combination for neuroblastoma: the vascular endothelial growth factor receptor/epidermal growth factor receptor/rearranged during transfection inhibitor vandetanib with 13-cis-retinoic acid.
Zage PE; Zeng L; Palla S; Fang W; Nilsson MB; Heymach JV; Zweidler-McKay PA
Cancer; 2010 May; 116(10):2465-75. PubMed ID: 20225331
[TBL] [Abstract][Full Text] [Related]
14. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Harding J; Burtness B
Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
[TBL] [Abstract][Full Text] [Related]
15. Expression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines.
Xu L; Hausmann M; Dietmaier W; Kellermeier S; Pesch T; Stieber-Gunckel M; Lippert E; Klebl F; Rogler G
BMC Cancer; 2010 Jun; 10():302. PubMed ID: 20565817
[TBL] [Abstract][Full Text] [Related]
16. Protein expression signatures for inhibition of epidermal growth factor receptor-mediated signaling.
Myers MV; Manning HC; Coffey RJ; Liebler DC
Mol Cell Proteomics; 2012 Feb; 11(2):M111.015222. PubMed ID: 22147731
[TBL] [Abstract][Full Text] [Related]
17. Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab.
Brand TM; Dunn EF; Iida M; Myers RA; Kostopoulos KT; Li C; Peet CR; Wheeler DL
Cancer Biol Ther; 2011 Sep; 12(5):436-46. PubMed ID: 21725209
[TBL] [Abstract][Full Text] [Related]
18. Responses of cancer cells with wild-type or tyrosine kinase domain-mutated epidermal growth factor receptor (EGFR) to EGFR-targeted therapy are linked to downregulation of hypoxia-inducible factor-1alpha.
Lu Y; Liang K; Li X; Fan Z
Mol Cancer; 2007 Oct; 6():63. PubMed ID: 17931419
[TBL] [Abstract][Full Text] [Related]
19. Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells.
Benavente S; Huang S; Armstrong EA; Chi A; Hsu KT; Wheeler DL; Harari PM
Clin Cancer Res; 2009 Mar; 15(5):1585-92. PubMed ID: 19190133
[TBL] [Abstract][Full Text] [Related]
20. The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors.
Huang F; Greer A; Hurlburt W; Han X; Hafezi R; Wittenberg GM; Reeves K; Chen J; Robinson D; Li A; Lee FY; Gottardis MM; Clark E; Helman L; Attar RM; Dongre A; Carboni JM
Cancer Res; 2009 Jan; 69(1):161-70. PubMed ID: 19117999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
